Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 2022

View Archived Issues

CD22 aberrant splicing confers resistance to therapy in B-ALL

Dysregulation of the tRNA synthetase modulator NOTCH1 behind T-ALL pathogenesis

Discovery of novel hybrid compounds as antitubercular agents

TuA-derived hPep elicits long-term anticancer immunity in mice

Leo Pharma discloses IL-17 modulators

Amgen and Arrakis collaborate to discover and develop targeted RNA degrader therapeutics

Anaxis Pharma patents MLKL inhibitors

Abbisko Therapeutics identifies new PD-1/PD-L1 interaction inhibitors

Betta Pharmaceuticals synthesizes new HIF-2alpha inhibitors

Wigen Biomedicine Technology presents new CDK inhibitors

CD6-ALCAM pathway is a therapeutic target in SLE

Methamphetamine harnessed for good in BBB transport

REVTx-99 demonstrates in vitro antiviral activity against SARS-CoV-2

PostEra and Pfizer expand strategic collaboration

VCAM-1-targeting polyelectrolyte complex enhances therapeutic efficacy of miR-92a inhibitors in vivo

Dren Bio and Pfizer collaborate to discover and develop bispecific antibodies for cancer

ABL and Sanofi enter collaboration and license agreement for ABL-301

G3PP is a therapeutic target for age-related metabolic diseases

Neogene licenses portfolio of TCRs targeting KRAS and TP53 mutations from NCI

A simple method for the synthesis of isoxazole derivatives with in vitro antitumor activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...